Last reviewed · How we verify
Technetium Tc 99M Sestamibi (TECHNETIUM)
Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue similar to thallous chloride TI-201, with possible mitochondrial retention.
Technetium Tc 99m Sestamibi, marketed by Cyclomedica, is a well-established agent for myocardial imaging with a strong presence in the diagnostic radiopharmaceuticals market. Its key strength lies in its mechanism of accumulating in viable myocardial tissue, offering an effective alternative to thallous chloride TI-201, which enhances diagnostic accuracy. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | TECHNETIUM |
|---|---|
| Sponsor | Cyclomedica |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1981 |
Mechanism of action
Technetium Tc 99m Sestamibi is a cationic complex that accumulates in living heart muscle tissue in a way similar to thallous chloride TI-201. This accumulation allows for scintigraphic imaging of both normal and diseased heart tissue, providing comparable images to those obtained with thallous chloride TI-201.
Approved indications
- Myocardial Imaging
- Breast Imaging
Common side effects
- Body as a Whole
- Headache
- Cardiovascular
- Chest Pain/Angina
- ST Segment Changes
- Digestive System
- Nausea
- Special Senses
- Taste Perversion
- Parosmia
- Breast pain
Key clinical trials
- Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (PHASE1)
- Repurposing Tilmanocept for Cardiac Sarcoidosis (PHASE2)
- SPECT/CT for the Characterization of Renal Masses
- EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers (PHASE2)
- Yttrium Y-90 Radioembolization in Treating Patients With Metastatic Liver Cancer (PHASE1)
- Tc99m Sestamibi Molecular Breast Imaging (NA)
- Comparative Analysis of Biotinylated, Irradiated and 51-Chromium Radiolabeled Red Blood Cells for Analysis of Recovery and Survival After Autologous Transfusion (PHASE1)
- Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Technetium Tc 99M Sestamibi CI brief — competitive landscape report
- Technetium Tc 99M Sestamibi updates RSS · CI watch RSS
- Cyclomedica portfolio CI